The magnitude of this differencebetween non-PCOS and PCOS was morepronounced at the higher doses of EPA (e.g., 1.42-fold at 25 μmol vs. 2.15-fold at 100 μM, P=0.008).Moreover, it was identified that the expressionlevel of CYP-19 was also influenced by the higherdoses of EPA in the PCOS GC as compared to thecontrol. The gene discussed is CYP19A1; the disease is polycystic ovary syndrome.